Exomas develops treatments for neurodegenerative diseases using neural stem cell-derived exosomes (CBSD-EXO). This technology stimulates the proliferation of existing neural stem cells and promotes neuroplasticity by generating new neurons. The goal is to restore mental and motor functions impaired by neurological damage.
Funding
$250K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SFounders
Product
Problem
Neurodegenerative diseases currently lack curative treatments, leading to progressive neuronal dysfunction, cognitive and motor deficits, and significant disability. Existing therapeutic approaches do not effectively address the underlying cellular damage or promote neural regeneration.
Solution
Exomas is developing a novel therapeutic platform utilizing neural stem cell (NSC)-derived exosomes, specifically CBSD-EXO, to address neurodegenerative conditions. This technology is designed to stimulate the proliferation of endogenous neural stem cells, thereby increasing the brain's cognitive reserve. Furthermore, CBSD-EXO promotes neurogenesis, facilitating the generation of new neurons and enhancing neuroplasticity. By replacing damaged cells and restoring neuronal function, this regenerative approach aims to mitigate cognitive and motor impairments associated with these diseases.
Target Audience
The primary target audience includes patients with neurodegenerative diseases and the medical professionals and researchers focused on developing treatments for these conditions.
Features
- CBSD-EXO technology derived from neural stem cells (NSCs)
- Stimulates proliferation of endogenous NSCs
- Promotes neurogenesis and neuroplasticity
- Induces neuroprotection by preventing neuronal apoptosis
- Restores neuronal morphology and function
- Enhances NSC differentiation into neurons
- Increases neurite outgrowth and dendritic spine density
- Augments Synaptophisin expression